Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Immunisation Against Streptococcus Pneumoniae
Interventions
OTHER

Synflorix™ data collection

Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01803425 - Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka | Biotech Hunter | Biotech Hunter